Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jay Hurh

Pain Medicine Libertyville, IL Medical Doctor

NPI 1225100712 CMS profile 100539

801 S Milwaukee Avenue, West Tower, Ll500, Libertyville, IL 60048

Open in the dashboard

General payments

$71,234

106 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jay Hurh of Libertyville, IL is reported in the CMS Open Payments database as having received $71,234 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,392 13
2024 General $5,885 15
2023 General $10,824 8
2022 General $15,044 20
2021 General $11,888 19
2020 General $6,649 11
2019 General $14,551 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jay Hurh
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jay Hurh were reported at $6,392. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Jay Hurh Pain Medicine median Middle half National median
2019 $14,551 $498 $126–$1,682 $163
2020 $6,649 $284 $80–$910 $114
2021 $11,888 $399 $112–$1,219 $132
2022 $15,044 $455 $137–$1,484 $149
2023 $10,824 $484 $128–$1,495 $160
2024 $5,885 $498 $131–$1,540 $164
2025 $6,392 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Avanos Medical $65,654 30 payments
  2. Medtronic, Inc. $1,991 13 payments
  3. Boston Scientific Corporation $1,822 16 payments
  4. Nevro Corp. $808 17 payments
  5. Abbott Laboratories $219 6 payments
  6. Medtronic USA, Inc. $180 2 payments
  7. Collegium Pharmaceutical, Inc. $146 9 payments
  8. Spinal Simplicity, LLC $118 1 payment
  9. Vertiflex, Inc. $61 1 payment
  10. Horizon Therapeutics plc $60 4 payments
  11. Other $175 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $61,555 15 payments
  2. Travel and Lodging $5,970 21 payments
  3. Food and Beverage $3,709 70 payments
Products named General payments · program years 2019–2025
  1. COOLIEF $54,378 20 payments
  2. COOLED RFA $5,750 2 payments
  3. COOLIEF* COOLED RADIOFREQUENCY $5,171 3 payments
  4. VANTA ADAPTIVESTIM $1,450 9 payments
  5. SUPERION $1,306 6 payments
  6. Senza $666 10 payments
  7. GENERATOR $355 5 payments
  8. INTELLIS ADAPTIVESTIM $338 2 payments
  9. Proclaim Family of SCS IPGs $183 4 payments
  10. OSTEOCOOL RF ABLATION $162 1 payment
  11. Other $1,320 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,592

Median for Anesthesiology: 322

Drug cost

$94,807

Median for Anesthesiology: $8,738

Branded share of claims

20.4%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 38 $31,059
Buprenorphine Generic 109 $30,887
Xtampza Er Oxycodone Myristate Brand 15 $12,941
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 173 $3,403
Methadone Hcl Generic 76 $1,768
Celecoxib Generic 51 $1,690
Morphine Sulfate Er Morphine Sulfate Brand 59 $1,675
Gabapentin Generic 144 $1,506
Pregabalin Generic 74 $1,275
Fentanyl Generic 13 $1,162

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$138,515

Of which drugs: $2,051

Medicare patients

424

Average age 74

Services billed

1,987

263 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 38%
Diabetes 32%
Ischemic heart disease 31%
Chronic kidney disease 31%
Osteoporosis 27%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record